Incretin mimetic therapy for type 2 diabetes has been on the market for more than 10 years. Find out what you've learned about the GLP-1 agonists, here.
Diabetes Type 2
The ADA provides an abridged version for PCPs of its annual Standards of Medical Care. Our slides summarize 6 updates important to primary care.
Contrave, a combination of naltrexone and buproprion, has been approved for long-term weight loss management in overweight and obese adults.
Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.
Early use of combination therapy to treat type 2 diabetes is shown to limit glucose toxicity and preserve beta-cell function.